Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sunrise Technologies

This article was originally published in The Gray Sheet

Executive Summary

Chapter 7 bankruptcy filing is made in Oakland, California district court to assist in liquidation of the Menlo Park firm's assets, which primarily relate to the Hyperion laser thermal keratoplasty system. The holmium YAG laser was approved in 2000 for temporary hyperopia reduction of up to 2 diopters by shrinking collagen in the eye. A March reorganization plan failed to gain sufficient support from secured creditors (1"The Gray Sheet" May 13, 2002, p. 12)...

You may also be interested in...



Financings In Brief

Alcon IPO: Swiss eye care company reports sales of $707 mil., up 8%, in its first quarter as an independent entity following its March 20 initial public offering of 76.7 mil. shares of common stock at $33 each - which raised net proceeds of roughly $2.4 bil. (1"The Gray Sheet" March 4, 2002, p. 22). Surgical unit revenue of $338 mil. was ahead 4%, anchored by AcrySof intraocular lens sales of $102 mil...

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017231

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel